



CORPORATE SUMMARY

CORPORATE HIGHLIGHTS

2001

- Inimex founded by Professors Brett Finlay and Bob Hancock, to develop therapeutics that activate the innate immune response without inflammation.

2002

- Worldwide exclusive licence to Inimex' intellectual property granted by the University of British Columbia.

2003

- Inimex co-founder Professor Hancock receives Aventis Pharmaceuticals Award, ASM's premier award in antimicrobial research.

2004

- Dr. Monisha Scott of Inimex named to the list of "The World's Top 100 Young Innovators" by Technology Review, MIT's Magazine of Innovation.
- Inimex co-founder Professor Finlay receives the 2004 Squibb Award from the Infectious Diseases Society of America.
- US\$6.9M series A Venture Capital Financing completed. Investors include: MDS Capital; BDC Venture Capital; Growthworks; Discovery Capital; and BC Advantage Fund.

2005

- Inimex co-founder Professor Finlay receives US\$8.7M grant from the Foundation for the National Institutes of Health and the Bill and Melinda Gates Foundation.
- Dr. John R. North named President & CEO.

2006

- \$US 3M Convertible Debenture Financing with full participation of existing venture syndicate.
- Selection of IMX942 as first IDR Development Candidate and Prevention of Fever & Infection in Hematopoietic Cell Transplant Patients as the first indication for demonstrating IDR Human Proof of Concept

2007

- Publication in Nature Biotechnology describing Inimex prototype IDRs
- Inimex co-founder Bob Hancock awarded \$100,000 Killam Prize for 2007

2008

- Inimex raises US \$22 million Series B Venture Capital Financing in the fight against antibiotic resistance

OVERVIEW

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body's innate defenses without causing inflammation.

Efficacy data in numerous animal models and promising safety data indicate the opportunity to develop multiple IDR products addressing significant unmet medical needs with major market potential. These medical needs include infections in immune suppressed patients, antibiotic resistant hospital infections (*e.g.* MRSA, VRE, and FQRP), and the management of inflammatory disease.

The Company's lead product, IMX942, targets a broad spectrum of life-threatening hospital infections, many of which are antibiotic resistant. The first clinical indication is the prevention of infections associated with chemotherapy. Additional product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.


TECHNICAL BACKGROUND

Individuals who have compromised immunity are at-risk for infectious disease, inflammatory disease, and cancer. Administration of IDRs to these individuals will selectively modulate and potentiate their innate defences, thereby tipping their physiological balance to help their immune system prevent disease.

Inimex IDRs are proprietary short synthetic peptides with prolonged biological effects on innate immunity. IDRs are readily manufactured, have long shelf-life, and are well tolerated *in vivo*.

Inimex' lead IDR product IMX942 binds to a novel target that modulates the function of adaptor proteins in the TLR signaling pathways. This suppresses the production of pro-inflammatory cytokines such as TNF- α and IL-6 while activating the transcription factor C/EBP to cause induction of the chemokines RANTES, MCP-1, and MCP-3. Rapid induction of these chemokines by IMX942 promotes recruitment of monocytes and macrophages to disease sites, speeding the resolution of bacterial infection without promoting the development of antibiotic resistance. Importantly, and unlike immunomodulatory drugs in development that bind to the Toll-Like Receptors of the innate immune system, IMX942 does not cause persistent activation of NFkB, the central transcription factor associated with potentially harmful inflammatory responses. The scientific background on IDR-1, a prototype IDR compound, was recently published (Nat. Biotechnol. Vol. 25 No. 4).

Inimex has a strong Intellectual Property position surrounding IDRs and the modulation of innate immunity for clinical benefit, including patent filings on compositions of matter, mechanism of action, and IDR assays. In addition, Inimex holds an exclusive license to key innate immunity patents from the University of British Columbia.



CORPORATE GOVERNANCE

Management Team:

John R. North, Ph.D.
President & CEO
Oreola Donini, Ph.D.
Senior Director, Preclinical R&D
Martin (Marty) McConnell, C.A.
Chief Financial Officer

Board of Directors:

Robert Fildes, Ph.D.
Chairman
Gerald Chan, Ph.D.
John R. North, Ph.D.
Brenda Irwin, M.B.A.
Pat Brady, M.B.A.
Michael Cross, Ph.D., M.B.A.
Brian Barber, Ph.D.

Scientific Advisory Board:

B. Brett Finlay, Ph.D., O.C., F.R.S.C.
Chairman
R.E.W. (Bob) Hancock, Ph.D., O.C., F.R.S.C.
Stanley Falkow, Ph.D.
Gordon Dougan, Ph.D.
Anthony Chow, M.D., F.R.C.P., F.A.C.P.
H. Grant Stiver, M.D.
Walter Singleton, M.D.

Contact Information

Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby, British Columbia
Canada V5A 4T8
P: 604-225-2251
F: 604-225-2257
www.inimexpharma.com
info@inimexpharma.com

MARKET OPPORTUNITIES

IDRs offer the benefits of significantly reduced morbidity and hospital costs for patients with infectious disease, cancer, and inflammatory disease.

Inimex' lead IDR product IMX942 is being developed for hospital administration in (1) Infections associated with Cancer Chemotherapy – Induced Neutropenia [600,000 U.S patients *p.a.*] (2) Cystic Fibrosis [Orphan Indication; 30,000 US patient prevalence with chronic treatment needs] (3) Post-surgical and Ventilator Associated Pneumonia [1 million U.S patients *p.a.*] and (4) Surgical Site Infections [700,000 U.S patients *p.a.*].


A second IDR product targeting inflammatory disorders would have the potential to address distinct and sizeable patient pools *e.g.* Rheumatoid Arthritis [2.9 million U.S. patients], Psoriasis [4.1 million U.S. patients], and Inflammatory Bowel Disease [1 million U.S. patients].

High growth benchmarks for IDR products in the above target markets include : (a) Colony Stimulating Factors (annual sales projected to grow from \$3.5B to \$4.9B by 2010) and (b) Biological anti-TNF- α agents (annual sales projected to rise from \$8.3B to \$17.1B by 2010).

PRODUCT DEVELOPMENT

Inimex' lead IDR product IMX942 is being advanced into formal development for the prevention of life-threatening hospital infections. Human efficacy of IMX942 will initially be demonstrated by the prevention of fever and infection in cancer patients undergoing hematopoietic cell transplant. These first patient studies will be followed by clinical development of IMX942 in substantially larger patient populations.

Additional IDR product development activity will focus on (a) defining a target indication and selecting a clinical development candidate for the management of inflammatory disease and (b) identification of small molecule products suitable for oral administration.



IDR Product Opportunities